ImmunityBio, Inc. IBRX
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Wait for Q2 report in August before taking new positions
FDA approval and the European launch improve the commercial prospects, while high burn rate and dilution risk support the HOLD signal.
Sentiment is predominantly positive on social media with focus on the European launch and confirmed commercial infrastructure.
HOLD is the call. Positive is the market mood. High risk means a lot can go wrong.
Latest change
- 5 Aug 2026 — Report issued 4 August shows sequential revenue growth and UAE approval as the drivers behind updated key figures.
About the company
ImmunityBio develops immunotherapies for cancer and infectious diseases. The lead product ANKTIVA is an IL-15 superagonist approved for non-muscle invasive bladder cancer in combination with BCG. The company is in early commercialization with strong revenue growth but continues to post large losses.
Bull case
Broader FDA indication and durable responses strengthen ANKTIVA’s commercial potential in NMIBC.
Bear case
High operational burn rate and capital needs continue to create dilution risk.
Why this signal
FDA approval and the European launch improve the commercial prospects, while high burn rate and dilution risk support the HOLD signal.
Recent news
ImmunityBio treated the first European patients with ANKTIVA plus BCG in Germany and Austria. The stock fell 10.3 % to 8.01 USD on 5 November after rising to 8.93 USD the prior day. The QUILT-2.005 database was locked with topline results expected in November.